life scienc tool diagnost
bottom line lead global manufactur distributor support
life scienc market highli lever
healthi industri fundament driver rise biopharma demand
innov geograph expans improv oper effici
support top-lin growth double-digit earn growth
next five year focu transform billion acquisit
laboratori supplier vwr novemb creat vertic
integr provid proprietari product suppli chain solut
robust life scienc industri tangibl synergi opportun near term
biopharma growth engin increment synergi driver
acceler pace scientif innov rise exposur faster-
grow biopharma end market sale compound-annual-growth-rate
support above-market growth increment driver
stem innov greater penetr higher-margin proprietari
consum sale vwr commerci synergi extend
geograph reach china drive increas volum vwr
channel vwr cost synergi million two year along broader
effici initi support bp ebitda margin
expans annual capit deploy focu de-lever
reach target leverag current
attract valuat share risen sinc ipo vs
 ev/ebitda share still trade meaning
discount competitor thermo fisher broader peer group
averag target price base ebitda
still discount peer better reflect build exposur faster-
grow higher-margin product line end market well line sight
near-term synergi risk includ fluctuat spend macro
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global manufactur distributor product
servic custom locat focus
biopharma life scienc end market
gener estim billion revenu
blue sky scenario predic better-than-
expect synergi captur relat vwr intern
acquisit continu improv effort driven avantor
busi system acceler penetr growth emerg
market well sustain strength biopharma end market
grey sky scenario base lower-than-expect
synergi captur relat acquisit
integration-rel miscu slow spend across
broader biopharma end market heighten competit
 close
tabl content
product servic
capit deploy focus de-lever
earn outlook financi resourc
compani data credit suiss estim billion
compani data credit suiss estim billion
figur revenu mix geographi
figur revenu mix end market
revenueorganic marginamerica technolog salesfrom life scienceskey end market estimate address market billion estim compound-annual-growth-rate research develop manufactur applications- small molecul pharma gener drugs- biolog biosimilars- vaccin cell gene therapi blood components- manufacturing- aerospac defense- chemical/petroleum- industrial- basic appli science- govern sponsor research across multipl area discovery- kit primari secondari scienc education- agricultur environment testing- medic implant drug deliveri devic non-implant devices- diagnost tool consumablestot address technolog educ charl martineau pm univers toronto
initi coverag outperform rate target
price global manufactur distributor product servic support
custom process earli develop full commerci end
product primarili focus biopharma life scienc appli technolog
market serv custom locat countri gener
billion revenu report organ
found legaci predomin manufactur consum
product includ high-pur materi use scientif research novemb
acquir lead laboratori supplier vwr intern billion estimate ntm
ebitda creat vertic integr provid proprietari product suppli chain
solut ad scale custom access life scienc offer tangibl
synergi opportun near term manufactur product suppli third-
parti product partner offer value-ad servic help
custom effici develop innov therapeut product
particip billion total address market grow compound-annual-growth-rate
above-market growth opportun focus faster-grow
end market biopharma innov geograph expans oper effici
initi support top-line growth double-digit earn growth
next five year summari believ benefit follow
robust structur tailwind particularli biopharma sale rise
healthcar cost associ age popul grow demand
treatment complex chronic diseas underpin secular trend current
fuel invest healthcar servic infrastructur research global
benefit healthi industri fundament forese futur
exposur biopharma industri sale fastest-grow end-market
compound-annual-growth-rate believ sustain tailwind
increas invest research develop novel product includ
emerg biotherapeut drive demand value-ad product
entrench custom relationship drive greater penetr innov
proprietari product increasingli view one-stop solut
custom highli embed associ workflow dynam leverag
along continu innov strengthen custom relationship importantli
avtr inher higher margin proprietari consum materi product
repres revenu grow healthi double-digit clip meaning
product innov inform inher entrench custom relationship
geograph expans focus high-growth market identifi five
faster-grow hub amea see favor underli market dynam
includ india korea/japan south east asia china
east/africa legaci meaning exposur amea market
sale combin compani gener sale
region leverag legaci avantor meaning brand presenc drive penetr
vwr busi expect geograph mix skew meaning toward
amea region time repres estim revenu
vwr acquisit synergi captur broader effici initi estim
achiev bp annual margin expans long term driven
disciplin busi ab importantli estim
million increment vwr cost synergi next two year driven
reduct sg procur effici manufactur optim
drive increas volum vwr channel
capit deploy focus de-lever billion debt net
leverag ratio focu debt pay near medium term
reach target leverag de-lever
strategi may turn disciplin longer term target leverag level
achiev emphasi enhanc capabl global footprint potenti
supplement growth annual
valuat share increas sinc may ipo vs
current trade ep ev/ebitda multipl
larger competitor thermo fisher ebitda went similar
transform transact thermo product manufactur fisher scientif
distributor target price base ebitda still discount
broader peer group life scienc compani better reflect build
exposur faster-grow higher-margin product line end market well line-
of-sight near-term vwr synergi
risk factor risk call includ govern spend cut fluctuat
biopharma manufactur spend macroeconom weak competit
life scienc sector advers chang custom purchas pattern custom
and/or vendor consolid channel conflict integr miscu foreign exchang
may complet initi public offer estim net billion
billion includ seri mandatori convert prefer stock note affili
new mountain capit affili goldman sach certain director execut
offer offer convers exist junior convert prefer
stock outstand share
ipo date
common share offer overallot provis fulli exercis pf basic share vs propos rang ipo billion execut overallot use proce redempt seri prefer share debt paydown control ownership new mountain capit goldman sach vs charl martineau pm univers toronto
lead global manufactur distributor product servic
custom locat countri exposur sever end market
includ biopharmaceut compani healthcar provid educ govern
agenc well manufactur util advanc technolog appli materi
avtr offer typic use research develop well product
process goal support custom effort develop new innov
product novel therapeut lower develop product cost improv
product process perform characterist enhanc safeti reliabl
drug devic product estim avtr total address market
opportun worth billion grow compound-annual-growth-rate
found john townsend baker baker chemic compani later
known avantor perform materi found univers student
studi chemistri need higher-pur materi complet coursework sinc
compani evolv meaning year includ noteworthi
product launch high-pur solvent product line chromatographi column
among other acquir covidien formerli tyco healthcar
subsist umbrella parent compani year privat
equiti firm new mountain capit acquir covidien subsequ
year complet sever acquisit bolster portfolio includ rfcl
india poch poland nusil technolog puritan product
recent largest acquisit date
estim gener billion sale three report unit
distinguish geograph region includ america europ amea note
disclos sale quantifi growth end-market decis made follow
acquisit vwr compani aim manag combin busi
geograph order improv focu high-growth region large-scal
corpor reorgan complet importantli
acquir vwr gener significantli greater sale ebitda
legaci busi stand-alone basi
figur sale mix segment
figur organ revenu growth segment
compani data credit suiss estim first nine month
gener sale america europ amea
unfortun vwr acquisit make histor revenu growth trend incompar
said organ basi grew revenu support
growth america europ amea continu
offer six million product custom includ manufactur
well product distribut behalf third-parti core supplier
maintain manufactur facil figur vast major facil
locat america remain facil locat intern avtr
global infrastructur also consist facil includ distribut network
support scalabl erp system enabl compani deliv broad array
product custom typic within hour despit america gener
well half compani total sale avtr distribut network
unsurprisingli skew toward intern segment market nation
regul oper local custom drive inher need local presenc
compani data credit suiss estim first nine month
compani data credit suiss estim first nine month
avtr global manufactur facil includ cgmp compliant facil
fda compar author regist facil support custom relationship
competit custom purif capabl figur facil
abl quickli adjust key specif product depend custom need
moreov maintain flexibl unit oper allow product scalabl
smaller quantiti pre-clin develop need large-volum commerci
requir therebi permit suppli product throughout entir life cycl
research develop commerci particular product enabl
custom go market faster also util proprietari purif technolog
design ensur lot-to-lot consist ultra-low impur level
support rigor analyt regulatori qualiti control procedur test
figur maintain global manufactur facil includ cgmp compliant fda
compet global scale util local presenc global
infrastructur foster stronger relationship custom locat
countri serv strateg partner includ sever larg
custom whose aggreg global spend exce billion annual
importantli singl end custom repres total sale moreov
deemphas potenti exposur particular custom mani individu
sale sale support profession establish long-standing
custom relationship evidenc fact revenu
gener client year relationship compani order support
relationship employ roughli account manag across product
line particularli address larger account requir high-touch sale model
includ key account manag cover top strateg account global
advanc technolog servic innov well sale support staff
provid local presenc smaller custom site requir lower level
support offer remot support sale custom servic
view avtr salesforc critic compon strategi success
compet competit market divers fragment competitor base also
highlight on-line portal sale gener million
user session million user last twelv month inher cost-
effici channel
figur maintain signific number
deep long-stand relationship
compani data credit suiss estim first nine month
compani data credit suiss estim first nine month
product servic
sell six million product global includ materi consum
equip instrument well offer servic specialti procur
note consum account revenu proprietari third-parti
importantli avtr revenu recur natur provid meaning level
visibl quarterli revenu trend potenti rel advantag life scienc
peer group gener lower recur revenu mix figur remain
total revenu gener sale equip instrument
primarili manufactur third-parti supplier albeit util avtr proprietari
brand mani case note legaci avantor revenu prior vwr transact
essenti proprietari product recur natur
figur product servic sale mix
compani data credit suiss estim first nine month
figur vast major revenu
consid recur natur
compani data credit suiss estim first nine month
revenu client year relationship gener on-line custom materi consum materi consum specialti procur instrument recur charl martineau pm univers toronto
figur recur revenu mix across life scienc peer group
highlight proprietari offer sale
importantli estim sale gener proprietari product
servic across materi consum servic specialti procur
remain sale deriv suppliers/partn includ ge healthcar
thermo fisher among sever other also often compet directli
offer note manufactur equip
instrument portfolio includ variou brand offer
figur third-parti supplier relationship proprietari offer across workflow
offer comprehens portfolio product divers applic includ
limit laboratori workflow biopharmaceut product biomateri medic
devic advanc technolog appli materi manufactur
semiconductor high precis electron well aerospac defens
applic figur avtr product valu exact puriti
perform specif key competit characterist custom choos
highli critic product research develop and/or product process
revenueproprietari product servicessuppli revenuemateri consumablesequip instrumentationservic specialti procurementbiorepositorycustom kittingclin trial totalmateri consum charl martineau pm univers toronto figur product type summari includ offer manufactur and/or distribut
offer distribut product variou third-parti core supplier
also highlight key proprietari offer also summar figur
 baker origin found baker long trust life
scienc electron materi custom product manufactur
puriti level stringent parts-per trillion ppt level brand one
wide known
respect brand chemic global serv
biopharmaceut semiconductor manufactur well environment test
prepar product high-pur acid biolog buffer reagent high puriti
endotoxin hple sugar process chromatographi media salt solut
photoresist stripper post-etch residu remov well innov packag
nusil year nusil provid medic space-grad high-
puriti silicon offer product formul librari applic
drug deliveri medic implant aerospac electron
vwr chemic vwr lead global provid product servic solut
includ thousand chemic formul manufactur exact qualiti puriti
perform packag specif product primarili util
scientist perform sensit analys microbiolog cell diagnost
product typeillustr productsworkflow applications- acid salt reagent solvents- inorgan compound metals- bioreagents- buffers- glasswar plasticwar pipettes- laboratori safeti products- inorgan salts- solvents- chelat agents- surfactants- high-pur acids- buffers- reagents- foams- gels- dispersions- acid solvent solutions- custom silicon formulations- filtrat systems- biolog safeti cabinets- viru inactiv systems- incubators- analyt instruments- evaporators- ultra-low temperatur freezes- critic environ supplies- microscopes- chromatographers- oxygen meters- mass spectrometersmateri consumablesequip instrumentationlaboratori chemic supplies- chemic research develop analyt test pharmaceut product applic microelectron product microbiolog testing- util daili oper lab span research develop test measur acoss multipl industries- aerospac defens industri applic chemicals/petroleum industri applicationsadvanc appli materialsequip instrumentation- research develop product workflow life scienc advanc technolog appli materi industriesbioproduct product chemicals- biolog qualiti assurance/qu control test biopharma product applic genom proteom cell cultures- high puriti silicon medic implant devic aesthet reconstruct implant deep brain stimul devic pacemak cochlear implant non-implant devic medical-grad tube balloon bladdersbiomaterials- use manufactur semiconductor high precis electron charl martineau pm univers toronto
genom proteom note estim legaci vwr sale
associ proprietari offer
ultra lc/m hplc gc applic typic use variou
chromatographi techniqu use separ compound well acid
chemic salt among product product primarili use expand
discoveri develop product laboratori pharmaceut
seastar seastar chemic manufactur high puriti reagent
use global research laboratori microelectron industri also qualiti
leader manufactur ultra-pur acid base product primarili util detect
trace element environment food semiconductor analysi test
benesphera benesphera offer cost-effect diagnost solut technolog
includ vitro reagent instrument clinic chemistri immunolog
microbiolog hematolog histolog elisa rapid card test genet test life
scienc research academia govern pharmaceut laboratori
product character state-of-the-art accuraci precis reliabl
well ease-of-us
laboratori glasswar among offer serv grow vari custom
base india relat region market
caresil caresil brand deriv nusil capabl util nusil
silicon innov leadership skin care market caresil silicon
technolog rang novel encapsul technolog gel deliveri system
activ cream light-refract phenyl silicon essenti wrinkl
poch establish polish laboratori market date back year
poch brand maintain reput offer variou chemic product
materi includ buffer standard volumetr solut compound silver
preciou metal laboratori consum equip polish
puritan product puritan product brand offer varieti gmp-manufactur
materi includ salt ph buffer acid among other pharmaceut
biopharmaceut semiconductor laboratori market product
manufactur avtr iso-certifi fda regist inspect facil
cgmp standard packag exact specif
charl martineau pm univers toronto figur proprietari brand summari sale
value-ad servic offer sale
also provid multipl value-ad servic well specialti procur
custom enabl custom fulli focu core compet figur
note servic account revenu grow low-doubl digit
tradit value-ad offer larg focu need laboratori
scientist includ procur logist chemic equip track
glasswar autoclav sinc expand offer includ addit
servic dna extract bioreactor servic clinic biorepositori servic
compound manag
current employ associ co-loc certain custom
perform servic essenti work side side custom scientist
offer also inher deepen custom relationship to-dat estim
servic associ return hour custom scientist drive
effici focus workflow importantli co-loc model also provid
deep insight custom workflow offer innov team
employe uniqu insight deliv increment sustain improv
exist product process
 high-pur solvents- reagents- high-pur acids- organ chemicals- ultra lc/ms- laboratori glassware- biolog buffer reagents- condens assemblies- high puriti endotoxin hple sugars- volumetr glassware- post-etch residu removers- membran filters- environment testing- adhes biomateri advanc chromatography- dispersions- instrument analysis- fluid foam gells- solvents- high consist rubbers- vitro diagnostics- liquid silicon rubbers- microbiology- primer resin greases- acids- elastom gels- buffers- encapsul nology- cleaners- specialti fluids- reagents- suspens nolog salts- volatiles- solutions- high-pur reagents- laboratori reagents- ultra-pur acid products- high-pur solvents- ultra-pur base products- filtrat materials- bottl top dispensers- chemic raw materials- trace metal analysis- preciou metals- product defens safety- acids- gmp-manufactur salt buffer acids- buffers- grade process chemicals- cleaners- fiberglass reinforc chemicals- reagents- chemic contract packaging- salts- hazard chemic manufacturing- solutions- contract manufacturingrankemnusilcaresilpochpuritan productsj bakervwr chmeicalsmacron fine charl martineau pm univers toronto figur avtr servic specialti procur sale
serv four end market includ revenu
healthcar educ govern well advanc technolog
appli scienc importantli revenu deriv life scienc
includ half revenu educ govern custom still
deriv one-third sale advanc technolog appli scienc market
servic typeillustr servicesworkflow applications- media buffer preparation- gxp sanitization- garment management- stockroom point use management- dna extraction- cell bank management- sampl processing- qc assays- regul research product clinic processes- secur sampl data management- custom kitting- clinic trial logisitics- hplc uplc gc mass spectrometry- benchtop equip instruments- pipett calibration- activ vendor management- applic customer-specif product sourcing- order confirm tracking- streamlin inventori processes- spend manag analytics- new product development- filtrat dialfiltration- downstream optimization- chromatograph processes- servic diagnost lab test kit build mainten clinical/biolog sampl control environ sotrat tissue/dna sampl identif cancer mutat clinic biorepositori services- custom design fabric single-us connector compon systems- vaccin pharmaceut protein monoclon antibodi processesbiopharma services- instal valid calibr prevent mainten lab equipment- equip manag solut includ vwr equip manag app- track equip servic manag need servic record prevent mainten schedul work order creationmarketsourc procur sourc services- raw materi character analysisequip services- inventori chemic manag solutions- lab-experienc profession perform protocol-driven workflowssci serviceonsit services- secur biorepositori preserv temperatur humid control environments- specialty-train associ perform on-site offsit oper laboratori product area charl martineau pm univers toronto
figur revenu mix end market
aggreg four serv end market form estim total address market
opportun billion figur largest fastest-grow opportun
resid biopharmaceut end-market account address
market grow estim compound-annual-growth-rate estim
total address market grow compound-annual-growth-rate
figur manag estim address market opportun industri sector
biopharma revenu
offer rang product servic support step
biopharmaceut product process span research develop phase
commerci serv biopharmaceut biotechnolog biosimilar
gener drug compani well contract manufactur organ cmo
leverag strong custom relationship serv top ten biotech
pharma compani maintain relationship biotechnolog
innov organ note top market biolog drug util
solut make biopharma industri revenu total revenu
estim address market biopharma industri billion grow
compound-annual-growth-rate fastest grow end-market
 technolog end market estimate address market billion estim compound-annual-growth-rate research develop manufactur applications- small molecul pharma gener drugs- biolog biosimilars- vaccin cell gene therapi blood components- manufacturing- aerospac defense- chemical/petroleum- industrial- basic appli science- govern sponsor research across multipl area discovery- kit primari secondari scienc education- agricultur environment testing- medic implant drug deliveri devic non-implant devices- diagnost tool consumablestot address technolog educ charl martineau pm univers toronto
view well-posit support emerg need provid solut
tradit small molecul complex larg molecul biopharma
repres key driver growth longer term explor
invest strength page moreov highlight sticki associ
biopharma product busi later stage product materi requir sever
month switch also high associ switch cost
figur deepli embed biopharma custom workflow
healthcar revenu
avtr healthcar segment offer product servic medic devic
diagnost industri offer includ high-pur silicon use manufactur
medic implant devic aesthet reconstruct implant pacemak cochlear
implant high-pur silicon specifi non-implant medic devic medical-
grade tube balloon bladder expertis custom sustain drug releas devic
pharma/biolog custom lab equip on-site servic well hematolog
immunolog histolog clinic chemistri estim address market
healthcar industri worth billion grow compound-annual-growth-rate
also highlight recur natur healthcar revenu experi
year recur revenu per project current estim biomateri sale
alreadi contract next five year enhanc visibl overal
boast robust pipelin customer-driven innov project also
custom relationship extend year
relationship top custom product sole-sourc
custom mean custom reli continu manufactur deliv
certain item sourc competitor note serv top
medic devic diagnost compani across end-market
strength
upstreamdownstreamfil finish sticki sticki contribut bio-pharma product materi requir switch yearscost switch per productup millionup million milliondrug registrationregulatori notif often requiredregulatori notif equival studiesclin studyproduct efficaci qualitycomposit may impact product formationimpact product formationcontrol drug stabilitysafeti effect drug homogeneitylarg effect drug homogeneitycontrol drug charl martineau pm univers toronto figur increas visibl biomateri
figur resound sticki healthcar
custom due singl sourc product
educ govern revenu
suppli materi consum well equip instrument
academ government-sponsor research laboratori predominantli focus
higher educ sub-seg also support agricultur environment
test offer varieti high puriti product hplc solvent solut salt
separ media well servic market repres billion
opportun grow estim compound-annual-growth-rate importantli
work top research univers us europ along
top five govern research agenc
look organ nation scienc foundat nation
institut nih fund thousand univers govern program
grant cooper agreement contract increas us
academ spend partial result strong nih fund expect
increas support end-market meanwhil europ
increas horizon research innov program also support
demand avtr product servic
advanc technolog appli scienc revenu
offer comprehens portfolio solut high-pur acid solvent
use manufactur semiconductor high-precis electron applic
well specialti space-grad silicon materi util aerospac defens
industri solar panel mar rover last well beyond predict
lifespan also support food beverag market chemic petroleum
well industri applianc total address market
billion grow compound-annual-growth-rate
serv four top five global semiconductor manufactur four top
five aerospac defens contractor note advanc technolog appli
scienc revenu highli recur natur proprietari formul typic
repres year recur revenu estim revenu
end-market alreadi contract next five year increas visibl
offer broad spectrum product servic across vari end
market highlight relev competitor also acknowledg
biomateri sale alreadi contract sole sourc charl martineau pm univers toronto
vwr acquisit also distribut mani product closest
competitor thu competitor perform alway indic overal share
shift traction across broader platform
figur product portfolio breadth competitor
thermo fisher lead provid instrument consum servic
custom engag scientif research rang pharmaceut
biotechnolog compani clinic diagnost laboratori academ government
research institut well custom industrial/environment industri
gener billion revenu four busi unit laboratori product
servic lp sale life scienc solut lss analyt
instrument ai specialti diagnost sd breadth solut
mean compet directli across key workflow includ media
genesi stem merger legaci thermo electron found
fisher scientif found creat one largest
diversifi compani life scienc tool industri sinc transform merger
compani pursu highli acquisit strategi expand breadth
product/servic offer geograph footprint organ inorgan
complet acquisit billion sinc
design manufactur market product servic profession
medic industri commerci use sale support strong brand name
major market posit innov technolog gener billion revenu
four busi unit life scienc sale diagnost
environment appli solut dental albeit compani
tickersal hostmg minim mediummediagrow inducingbioreactorsdisaggregationbufferingcleaningprocess chromatographyprotein solubilizationlys clean charl martineau pm univers toronto
expect spin dental unit via ipo conjunct pend
acquisit biopharma segment
distribut sever dhr product includ materi consum
pall brand well equip instrument offer
legaci vwr distribut channel avtr proprietari materi
consum well equip instrument sometim compet
brand particularli relat media buffer process chromatographi
filtrat among other note recent acquir ge biopharma billion
februari billion ad billion bioprocess revenu significantli
enhanc presenc chromatographi single-us technolog cell cultur media
view transact testament avtr grow focu biopharma
merck kgaa scienc technolog compani gener billion
revenu report growth stem healthcar sale life scienc
perform materi healthcar segment compris two
busi biopharma discov develop manufactur
pharmaceut prescript drug well allergopharma leader field
allergi immunotherapi europ meanwhil merck life scienc unit
lead global supplier tool high-grad chemic equip academ
laboratori biotech biopharmaceut manufactur well industri
sector perform materi segment compris specialti chemic busi
provid display solut semiconductor solut surfac solut merck
provid servic across entir workflow directli compet certain case
upstream downstream fill/finish process
becton dickinson medic technolog compani gener billion
revenu medic life scienc intervent busi life scienc
segment gener billion revenu preanalyt system life
scienc sale diagnost system bioscienc divis note
octob sold advanc bioprocess busi million
preanalyt system busi offer integr platform specimen collect
blood collect bioscienc unit offer fluorescence-activ cell sorter
reagent analyz among product line said compet
directli bdx diagnost system unit cell cultur media offer
sartoriu global pharmaceut laboratori equip supplier gener
billion revenu produc precis scale laboratori industri use
well electrochemistri also manufactur equip biomolecular microbi
separ concentr ferment cell cultur purif note compet
directli process chromatographi note distribut number
sartoriu product vwr channel includ pipettor pipet tip water
billion revenu ajinomoto japanes food biotechnolog
corpor produc season cook oil
sweeten amino acid pharmaceut diversifi food busi
inher less relev ajinomoto compet directli upstream
product workflow specif growing/induc
tosoh diversifi japanes chemic specialti product materi group
compris compani global gener billion revenu
establish tosoh focus commod chemic product line industri
specialti product materi high-end technolog nich market
primarili serv chemic petrochem construct automot consum
electron inform technolog bioscienc environment market note
tosoh primarili compet process chromatographi market albeit
vwr support distribut chromatographi column among offer
billion revenu bio-rad leader develop
product specialti chemic use biochem pharmaceut life
scienc research applic life scienc segment sale develop
manufactur market reagent laboratori instrument clinic
diagnost segment design manufactur sell test system test kit
informat system note bio-rad compet growing/induc process
well process chromatographi
bio-processing-focus life scienc compani gener billion
revenu notabl demand product driven overal
volum mab manufactur compet growing/induc workflow
process chromatographi
broader life scienc tool diagnost peer group
directli compet compani across life scienc
tool diagnost landscap perkin elmer among
other compani play similar underli fundament trend offer
baromet avtr perform underli demand trend relev end market
highlight rel size revenu peer compani well
compani organ growth trajectori past two year figur
figur organ growth rate life scienc tool diagnost peer group billion
establish leader life scienc tool diagnost industri
global scale commerci reach diversifi product offer leverag
size scale provid vast spectrum proprietari third-parti materi
 consum equip instrument servic research scientist
across varieti industri includ biopharma healthcar educ govern
advanc technolog appli materi benefit healthi
industri fundament forese futur rel robust demand across
rise healthcar cost associ age popul grow demand
treatment complex chronic diseas underpin secular trend current fuel
invest healthcar servic infrastructur research global accord
evaluatepharma global pharmaceut spend expect rise
billion see figur coincid us nation healthcar expenditur increas
compound-annual-growth-rate figur structur tailwind
continu drive greater demand diagnost novel biolog therapi address
world complex oner diseas threat cancer alzheim
arthriti diabet heart diseas simultan discrep standard
environment manag food safeti across nation narrow emerg
market step regul confront concern food insecur pollut
figur histor project global spend bln
evaluatepharma world preview outlook credit suiss estim
healthi fundament backdrop well-posit captur increment market
share given increasingli comprehens offer evolv one-stop shop
life scienc tool space magnifi extens suppli chain presenc vwr
govern academ institut corpor look curtail budgetari restrict
consolid spend avtr broad product offer proprietari third-
parti materi consum equip instrument relev servic allow
compani support custom across entir workflow portfolio
support avtr extens vwr intern suppli chain on-line platform
sale broad-bas custom exposur singl end custom
contribut net sale well embed relationship
associ co-loc certain custom enabl inform prioriti
identifi new technolog applic better meet custom need
figur escal us nation healthcar expenditur bln
center medicar medicaid servic credit suiss estim
view avtr diversifi platform competit advantag particularli given
biopharma healthcar
academic/govern advanc technolog appli materi industri
demand dynam
track multipl data point measur health biotech fund environ
accord bioworld comprehens data sourc biotech fund includ
public privat sourc increas april sequenti deterior
growth march figur figur overal biotech fund rose
heel jump caveat emphas fund stem
multipl sourc may fulli repres data instanc larg
pharmaceut compani repres key sourc fund small mid-siz
biotech compani inher insul broader capit market activ
ventur capit public market fund
figur quarterli overal biotech fund incl public offer fund public biotechnolog
compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
biotechspublic/otherpubl growth tough comp charl martineau pm univers toronto
figur monthli overal biotech fund incl public offer fund public biotechnolog
compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
educ govern fund remain healthi
repres total revenu govern fund often key
area investor focu organ nation scienc foundat
nation institut nih fund univers govern program
cooper agreement grant contract follow robust nih fund increas
billion like support rise us academ spend nih
fund increas slightli moder rate billion still
better ten year compound-annual-growth-rate budget lock acknowledg
fund may repres overhang particularli elect cycl note
trump administr consist sought nih fund cut excess
widespread bipartisan congression support result signific annual
increas nih fund recent year trend may continu view
figur nation institut nih billion
note estim base compound-annual-growth-rate
biotechspublic/otherpubl yoy growth charl martineau pm univers toronto
europ take closer look horizon program laid european union
parliament support academ commerci research across member
state contribut countri current program horizon includ
billion fund dedic research invest seven year
eu budget implement increas horizon program note
demograph chang well-being budget particular receiv boost
encourag dynam
importantli april european union parliament announc next larg research
program known horizon europ run
billion fund offer near-term comfort stabil research
scientist worri impact eu parliamentari elect remind eu
broad-rang research program began horizon europ program
repres ninth segment seri research fund associ
program account eu member govern spend total annual
figur european union research develop fund program
compani data credit suiss estim euro billion
govern fund dynam may expos life scienc peer volatil
posit fund news drive increment upsid tighten budget drive potenti
downsid note rel less expos govern educ
fund closest peer thermo fisher figur provid rel stabil
initi fund valu encourag note program final
continu seek updat
figur govern educ fund exposur across life
advanc increas demand high-pur materi
also highlight posit trend advanc appli materi
repres sale
automobil
consum electron
relat advanc technolog market semiconductor pervas
throughout daili live manufactur util materi varieti end-
make
semiconductor manufactur requir high-pur chemic product process
includ etch clean importantli jt baker product line origin
compani known today develop brand abil produc high-
puriti acid solvent proprietari chemic blend
stringent
requir demand semiconductor process
benefit increas use semiconductor technolog advanc
also benefit miniatur technolog trend requir
manufactur step greater puriti higher quantiti process materi
meet
health industri cs remain structur bullish
sector view revenu growth pois move minu plu
asp growth driven softwar industri develop new applic
demand faster expens chip oppos compani
rais like like price understand health market look
sarbanes-oxley figur suggest recognit continu
expand valu semiconductor industri
aerospac defens industri favor macro term strong defens budget
increas nato fund support demand moreov note legaci
platform current go upgrad cycl drive demand variou
custom silicon high-perform materi importantli term custom
formul silicon market leader year experi
market abil manufactur custom formul meet stringent requir
highli complex system
exposur divers set end market help provid hedg abnorm
volatil particular industri expect focu biopharmaceut
end market acknowledg largest opportun account
address market grow estim compound-annual-growth-rate ahead
total address market growth importantli provid comprehens
one-stop solut across biopharma workflow support custom discoveri
develop
commerci materi consum
instrument servic
recent quarter biopharma custom base meaning driver
organ revenu growth grow healthi high-single-digit clip
avtr biopharma segment acceler low doubl digit driven greater
penetr combin commerci platform strong perform across
product categori geographi note strength europ albeit potenti
attribut part custom stock ahead brexit unquantifi
figur histor revenu growth custom group
reflect legaci avtr perform pro forma reflect full year
momentum across biopharma end market continu fuel favor global
secular healthcar driver includ previous highlight factor age
demograph strong fund extern drug discoveri well
rise innov develop specialti medicin address challeng
associ chronic diseas overal matur sophist standard
medic care
research develop life scienc market remain healthi varieti
sourc includ govern startup larg pharmaceut compani
invest billion annual specif relat biopharma market
preclin research leader charl river laboratori note small mid-siz
biopharma compani grow faster top global biopharmaceut
compani key growth driver sell proprietari product well
suppli third-parti offer support emerg compani
burgeon develop pipelin biotech compani continu play
increasingli import role drug develop continuum innov engin
less total pipelin attribut top biopharma
accord iqvia institut given biotech increas ownership global
pipelin industri unsurprisingli larger better fund decad ago
includ compani activ biopharma pipelin
figur percentag late-stag pipelin compani size emerg
support aforement healthi fund dynam approach global
concern innov research singl cell proteom analysi
spur introduct novel therapeut grow focu person medicin
target therapi improv overal valu health outcom term
approv larg molecul drug approv last year us food drug
administr fda repres total approv new high water mark
industri figur biolog drug approv see increas
divers biolog mab repres roughli approv larg molecul
drug rprotein rna therapeut
also highlight next-gener ngb cell gene nucleotid
therapi account overal pipelin accord iqvia institut
doubl number sinc reach compound end vs
acknowledg drug class rel infanc though
late-st ngb pipelin phase ii develop moreov three ngb launch
bring total number ngb market
charl martineau pm univers toronto figur fda approv
compani data drug administr
compani data drug administr
new larg molecul drug come market biolog continu repres
grow portion effort product larg molecul sale continu
grow healthi clip accord evaluatepharma biolog sale grown
compound-annual-growth-rate expect grow compound-annual-growth-rate
repres nearli billion sale figur
figur biolog drug sale billion
expect outsiz growth biolog sale manufactur focu less small
molecul therapi larg molecul drug price reflect complex
costli natur develop process accord evaluatepharma biolog spend
increas percentag overal spend pharmaceut long term
rise shift mind biopharma compani
priorit larg molecul project view avtr growth strategi well-align
favor market dynam expand overal focu biopharma end market
moleculelarg moleculemab charl martineau pm univers toronto figur world-wide prescript sale biolog rise proport spend
evaluatepharma world preview outlook credit suiss estim
solut provid biopharma
said overal focu demand biolog continu rise oner
regulatori backdrop drug price reimburs pressur rise threat
generic/biosimilar disrupt overal rise cost complianc amongst
factor led profit deterior across biopharmaceut industri
figur deterior econom larg cap
deloitt credit suiss estim million
figur lower return larg cap
mean address profit headwind across industri biopharmaceut
compani develop highli complex costli therapeut immuno-oncolog
treatment seek expedit time-to-market potenti candid also ensur
innov qualiti control importantli efficaci given conflict pressur
well-posit assist custom across entir biopharma workflow help
achiev greater effici channel act
one-stop-shop solut facilit access laboratori product across numer
workflow span equip associ consum therebi allow custom
streamlin research necess singl vendor
biolog spend totalestim convent drug spend estim spend bring asset marketforecast peak sale per charl martineau pm univers toronto
biopharma may seek cost effici input highlight rel
shield dynam raw materi proprietari third-parti
materi sell custom repres total end product revenu
roughli cost good manufactur importantli biopharmaceut
compani like focus contain cost includ product
product support overhead oppos raw materi spend certain
materi may use risk mitig among benefit total cost good
manufactur grow two-year compound-annual-growth-rate raw materi grow
rapid clip two-year compound-annual-growth-rate due aforement benefit higher qualiti
figur biopharma industri good
manufactur composit billion
figur biopharma expenditur raw materi
billion
proprietari parti products- pb buffer- proteas inhibitor- extract buffer- spe columns- lc-m solventsvacuum centrifug me bufferfilt planes- micro-centrifugevacuum pump- centrifug tubes- chromatographi vialsautom liquid handler- seal matsrobot pipet tips- lc-m solvents- lc-m columnslc-m standards- ga generatorhplc syringe- wast containerhomogenizershimadzusampl isolationsampl prepsampl handlinglc-m analysisdata supportqc qaoverheadassetraw address charl martineau pm univers toronto
maintain customer-centr framework extens custom relationship
well embed posit associ workflow provid compani
enhanc revenu visibl uniqu insight custom prioriti may
use discern inform align effort key area custom
focu continu invest new technolog infrastructur improv
oper process enabl compani strengthen custom relationship
effect becom one-stop solut custom also becom
specifi custom new product workflow foster stronger custom
relationship durabl revenu stream thereon view current proprietari
offer continu innov drive stickier custom relationship
also help expand avtr address market opportun custom relationship
expand newli develop product supplement growth
repres total sale offer proprietari product variou brand
includ jt baker nusil vwr chemic among other see page
detail note avtr proprietari product revenu grow double-digit
also serv drive margin improv inher profit offer
util certain raw materi includ avtr proprietari offer
particularli sticki across biopharma product switch across workflow
costli may take extend period time anywher six month five year
potenti influenc all-import product efficaci qualiti safeti light
dynam avtr abil scale suppli product raw materi
research develop phase commerci therebi provid
element stabil biopharma compani remain key valu proposit support
custom cost contain effort time-to-market also drive stabl
recur revenu flow note avtr biopharma revenu deriv
rel sticki portion custom workflow downstream fill/finish
figur deepli embed biopharma custom workflow
innov strategi includ team includ scientist engin
sever hold phd advanc degre engag custom earli
product develop cycl identifi support effici journey
discoveri develop commerci innov team primarili work
avtr seven strateg locat develop center around world notabl
bridgewat new jersey site first open includ robust applic
upstreamdownstreamfil finish sticki sticki contribut bio-pharma product materi requir switch yearscost switch per productup millionup million milliondrug registrationregulatori notif often requiredregulatori notif equival studiesclin studyproduct efficaci qualitycomposit may impact product formationimpact product formationcontrol drug stabilitysafeti effect drug homogeneitylarg effect drug homogeneitycontrol drug charl martineau pm univers toronto
test facil custom co-develop capabl focu larg molecul
drug biolog also note expect open eighth innov center
locat shanghai china fulli oper
avtr team remain engag custom throughout entir innov cycl
support effici time dialogu leverag relationship help
identifi innov focu area drive develop new product line new
chemistri next-gener program importantli also tailor strategi
respect product line focus effort larg molecul biopharmaceut
custom silicon formul drug deliveri biomateri purif method
research extrem perform endur advanc technolog figur
key area focu
success improv given process particular client
leverag innov solut scientific/workflow expertis across broader
custom base allow deliv increment valu broader custom group
also inher improv posit earn potenti
figur innov area focu
today global footprint consist facil locat countri
enabl effect deliv million product servic custom nearli
anywher world gener within hour continu focu
expand geograph reach particularli current under-penetrated market key
growth driver come year dilig target market favor
underli demand trend grow exposur biopharma/pharma industri
strong growth characterist mind identifi five key hub
includ india korea/japan south east asia china
east/africa area target expans
specif biopharma/pharma industri qualiti regulatori requir
becom increasingli stringent mani emerg market drive local demand
avtr product solut moreov local supplier base seemingli
inadequ meet grow market avtr custom expand presenc
avtr target hub top custom alreadi hub market
particularli local govern increas invest support innov drive
bioproductionfocu broaden rang process ingredi serum reagent excipi chromatographi resin single-us assembliescustom manufactur product current customer-direct project develop across seven exist innov center global notabl partner custom creat solut meet stringent specif current futur product focu increas number product specifi certain custom workflow drive inher stickier relationshipnew product high growth segmentstak deeper look emerg technolog well regulatori industri standard make target invest develop relev solut cell gene therapi focu allow assist custom dynam end market environ drive effici commerci processservic offeringsad innov flexibl custom solut custom outsid tradit servic offer specialti procur focu help deepen relationship custom also allow gather increment insight workflow custom co-loc associ typic work side-by-sid custom scientist note small portion revenu value-ad servic grow double-digitsdigit capabilitiesbuild suit technology-en offer data gener custom help increas product effect research manufactur workflow charl martineau pm univers toronto
demand comprehens distribut channel leverag avtr vwr
oper well avtr product servic
figur identifi geograph expans
legaci stand-alone meaning exposur amea market
total sale legaci vwr oper rel under-penetrated
region repres sale aggreg combin compani
gener sale amea region view compani
abl leverag legaci meaning brand presenc platform know-how
region extend vwr geograph reach across high-growth market
geographi
revenu mix geographi
notabl combin compani sale gener amea region includ
asia-pacif substanti lower peer group averag
repres signific opportun view longer term
expect geograph mix skew meaning toward amea region similar
legaci stand-alone mix peer group priorit market
opportun said shift take time forecast gener
revenu amea region bp
figur life scienc peer group asia-pacif sale total sale
note sale comparison apples-to-appl given exposur includ region outsid asia-pacif region
includ middl east africa
expand amea exposur proactiv deploy growth model
associ market shown figur alreadi implement
essenti entir model india korea south east asia view particular
increment opportun india south east asia region togeth could deliv
half amea revenu meanwhil expect invest china
east/africa particular china expect increas invest
biotech insofar sector repres notabl trend
china includ ventur capit privat equiti invest healthcar reach
billion y/i biolog forecast increas compound-annual-growth-rate
vs us ventur capit buy us intellectu
properti molecul licens china market broader trend
repres meaning growth opportun expand across region
forecast sustain sale growth amea region next
five year repres sale today
figur model drive growth geographi
figur amea expect revenu growth trend million
forecast ebitda margin expand bp annual driven
integr synergi vwr busi ab broader
avtr current high fix cost model enabl strong increment volum
convers also ampl suppli chain capac amidst on-going manufactur footprint
optim facilit oper margin leverag rise exposur inher faster-
grow doubl digit higher-margin proprietari product current sale
also drive profit margin expans meanwhil also benefit
model moreov high product turnov on-going opportun
compani data credit suiss estim billion
revenu total charl martineau pm univers toronto
close transform acquisit novemb
made meaning progress initi integr effort synergi captur thereon
integr process track ahead plan current one-third way
detail three-year plan expect gener million commerci
million cost million synergi year three synergi captur
million merger-to-d run-rat save million ytd estim increment
million synergi next two year driven reduct sg
procur effici manufactur optim drive increas volum
vwr channel
context histor sole product compani gener
revenu proprietari materi consum essenti recur
natur howev follow vertic transact vwr global manufactur
well distributor laboratori product product servic avtr product
servic mix well recur revenu mix shift meaning proprietari
materi consum repres total sale exposur
recur revenu stream also decreas rel legaci compani
moreov vwr acquisit increas revenu ebitda
respect light aforement acquisit consequ transform
view substant opportun increment synergi captur two platform
manag integr busi remov duplic effort optim
figur revenu mix prior vwr
figur revenu mix follow vwr
current maintain integr program program specif
timelin overal effort support risk mitig program integr
manag team execut leadership enhanc convict abil
achiev state synergi target importantli commerci synergi repres
total synergi opportun million primarili predic provid
comprehens offer exist custom geograph expans previous
under-penetrated market discuss previous well abil drive legaci
avtr higher-margin proprietari materi consum product vwr
channel view commerci opportun achiev focu
tangibl cost synergi opportun
proprietari materi consum recur materi consum materi consum specialti procur instrument recur charl martineau pm univers toronto
figur target million synergi year three commerci vs
save repres bulk near-term synergi opportun million realiz
date deriv procur spend improv manufactur optim
along sg broader effici initi combin compani note
achiev million increment cost save continu target
addit million cost synergi balanc year
compani data credit suiss estim million
break key near-term synergi mileston anticip increment
million cost synergi stem multipl initi unquantifi
detail
headcount optim combin two platform address
redund unnecessari role ration footprint appropri exit
facil geographi etc simultan optim associ headcount
procur initi expect engag certain sourc initi
wherebi renegoti contract certain supplier distribut product
commerci synergi synergiesimpl implement implement charl martineau pm univers toronto
raw materi use product among area order improv cost
footprint ration consolid certain chemic manufactur site
well transfer product line cost effici locat
expens manag aim better control spend miscellan
off-shore conjunct headcount initi wherebi expect termin
local associ posit certain markets/geographi add associ
off-shore locat appropri facilit geograph reach
duplic expens one obviou area cost reduct expect
remov non-headcount duplic cost legal counsel cost expens
chemic strategi also target improv gross margin relat
compani data credit suiss estim million
continu oper improv support ab
increment aforement synergi opportun continu leverag
avantor busi system ab framework similar concept danah busi
db support dilig effici initi margin leverag longer term
ab drive continu improv creat support assist effort
tie critic busi process particular emphasi innov commerci
oper function
synergi captur relat vwr intern acquisit well continu
improv via ab initi support estim ebitda margin expans
bp annual next five year
capit deploy focus de-lever
continu earn growth momentum expect avtr cash reserv expand
capit deploy strategi focu de-lever near medium
term follow longer term note indic intent initi
conjunct initi public offer receiv billion net proce
use billion fulli redeem seri prefer stock intend use
remain proce repay million million outstand indebted
dollar term loan facil euro term loan facil
respect avtr total debt current stand billion impli net leverag
ratio ttm ebitda avtr debt load remain meaning elev
highlight manag aggress debt pay strategi begin immedi
target net leverag ttm ebitda ye fuel strong cash
gener dd ebitda growth
figur project net leverag trajectori net debt ltm adj ebitda
first prioriti de-lever target leverag level achiev
expect disciplin supplement growth annual longer term
importantli like target busi enhanc current workflow solut
strengthen strateg approach technic capabl and/or expand custom
figur notabl acquisit vwr
targetworkflow laboratori medic equip ancillari suppli clinic trialsepl biorepositori servic organ paw distributor sanitari fluid handl pre-packag conveni kit procedur high-pur fluid handl compon custom engineerd solutionsintegra singl use connect solutionstechn capabilitiestargetsdateacquirerdetailsseastar high puriti reagentsreli high qualiti activ pharmaceut ingredi high puriti ingredi us origin serum-bas medic space-grad siliconeshichrom distributor high perform liquid chromatographi column supplier high qualiti biochem reagentsgeograph manufactur distributor laboratori product product servicesjm single-us fluid handl separ technolog product distributor poland rfcl laboratori pharmaceut market charl martineau pm univers toronto
earn outlook financi resourc
review avtr revenu rose billion pro forma basi
support organ growth benefit fx note highlight
avtr year-over-year growth pro forma basi fulli reflect vwr
america segment experienc growth includ organ
growth larg predic higher volum well price improv albeit
lesser extent global valu captur program contribut million net sale
growth end-custom perspect experienc above-market growth
educ govern custom via meaning account win
meanwhil biopharma experi robust low doubl digit product
perspect proprietari materi consum acceler growth strength
equip instrument sale low doubl digit driven robust invest
biopharma primari educ govern sourc also experienc low-double-
digit growth servic continu leverag uniqu posit drive
europ experienc growth organ includ fx headwind
higher volum signific chang price global valu captur
program contribut million net sale growth end-custom
perspect higher demand largest custom drove strong biopharma growth
meanwhil lower growth healthcar educ govern custom
larg driven constrict fund sever european govern product
perspect sale growth proprietari materi consum attribut part
sale production-grad biopharmaceut product partial off-set lower growth
equip instrument
amea experienc growth organ larg predic higher
volum trend continu experienc low-doubl digit growth
across product custom group note largest custom region
biopharma advanc technolog appli materi industri
adjust gross margin sg repres sale
drive adjust ebitda margin oper incom
offer year-over-year comparison compar prior year metric
figur revenu growth custom product group
forecast project avtr revenu increas organ
bp fx headwind predic organ growth america europ
amea substanti acceler amea organ growth predic
increas invest manag focu region outlin invest
strength forecast million vwr synergi captur primarili relat
greater oper effici potenti upsid
potenti commerci
opportun forecast ebitda margin expans bp contribut
ebitda growth y/i larg predic aforement synergi captur
well continu effici initi leverag busi ab
effort also expect pay billion debt reflect
de-lever ipo proce well increment million pay
custom groupproduct groupbiopharma hsdproprietari materi consum hsdhealthcar msdthird-parti materi consum msdeduc govern hsdservic specialti procur lddadvanc appli materi msdequip charl martineau pm univers toronto
drive net interest expens million expect aforement factor
drive ep growth
long-term outlook long-term basi expect achiev mid-single-
digit high-single-digit rang top-line growth laboratori product industri
demand growth above-market growth driven biopharma product
biomateri amea servic among factor contribut increment
term profit expect bp margin expans annual volum
leverag integr synergi price acumen disciplin product mix benefit
shift proprietari materi consum busi ab
initi next five year expect ebitda margin expand bp
aforement factor
also expect proactiv de-lever per year like hit target
leverag rang moreov longer term follow period
de-lever potenti acquisit could add top-line growth annual focu
enhanc workflow geograph coverag accret thought
million cash reserv billion debt capit deploy
effort focus de-lever near term estim gener
million million cash flow oper respect
cash flow growth driven oper leverag particularli aforement
cash convers cycl day compar favor thermo fisher scientif
lower day inventori outstand like avtr rel greater exposur
proprietari materi consum lower equip instrument mix
well higher day payabl outstand said expand geograph
target custom emerg market would expect cash convers cycl
lengthen geograph expans typic requir addit inventori hold
potenti lenient collect term
figur convers cycl million
cut govern spend nih fund strong recent year rise mid-
singl digit high-singl digit past four year notabl govern
shutdown earlier year impact nih fund current fund
septemb said us feder budgetari debat like persist
repres consist overhang industri peer uncertainti
futur fund tradit earmark biomed research march presid trump
propos decreas nih fund part white hous budget plan
repres third time sought cut fund nih propos
despit initi propos nih fund increas gener
widespread bipartisan support congress ultim result substanti annual
increas late view discuss around govern spend continu
drive volatil though note rel less exposur compar
direct end custom
fluctuat slow manufactur spend broader slow
manufactur spend
biopharmaceut biomateri diagnost electron aerospac defens
research compani could signific advers impact demand avtr
product factor impact custom budget includ need develop new
product continu avail government fund competit
avail resourc importantli avtr contract gener contain
minimum purchas requir sale subject demand variabl client
could drive materi fluctuat year year even quarter quarter
macroeconom downturn revenu rel well diversifi across end
market deterior macroeconom condit could pressur top-line sale growth
particularli advanc technolog appli materi market also
government agenc
biopharmaceut compani although industri constitu character
strength biopharma sustain neg develop potenti spur
on-going polit risk slowdown overal demand would pose meaning
headwind avtr organ revenu growth trajectori
healthcar
competit dynam face competit across product market
oper competit driven primarili proprietari technolog
price valu speed competitor includ larg multi-national compani may
greater resourc financi market oper etc well
region compani may benefit geograph proxim quickli
respond custom need
custom purchas pattern avtr custom experienc like
continu experi signific industry-rel chang could advers affect
demand avtr offer industri chang includ develop group
purchas organ on-lin auction site increas competit reduc
spend lab product increas regulatori scrutini drug product requir
safer raw materi custom purchas direct manufactur rather
custom purchas impact price custom will
pay product
industri consolid consolid across biopharma healthcar industri
impli fewer custom account concentr purchas decis drive
increas price pressur avtr product larger impact
merger acquisit space includ bristol-my squibb recent acquisit
celgen januari takeda pharmaceut acquisit shire may
johnson johnson acquisit actelion januari trend expect continu
biopharma compani aim leverag scale gain expertis off-set
pressur increasingli stringent regulatori environ drug price
channel conflict given role largest supplier self-manufactur third-
parti laboratori equip consum vwr intern channel
vwr largest custom simultan oftentim signific competitor
chang competit dynam discontinu third-parti relationship may
integr risk may abl integr merger acquisit
success exist busi includ recent transact vwr
notabl success integr acquisit
process take longer expect may affect avtr abil realiz anticip cost
save addit sale opportun time manner moreov integr effort
may requir certain instanc substanti manag resourc may distract
manag attent day-to-day busi oper
avail raw materi avtr abil obtain high-qual raw materi
includ api compon compound excipi among raw materi
commod price thereon could advers impact compress margin
maintain adequ suppli raw materi impact avail
price materi well relationship key supplier depend
regular deliveri particular supplier interrupt deliveri could
advers affect oper establish arrang altern supplier
typic determin qualiti cost regulatori requir need
commerci viabl manufactur product
global trade dynam acknowledg inher risk potenti fluctuat
global trade dynam china mexico relat china
know avtr explicit exposur countri note amea sale repres
total sale geograph segment includ number
countri across asia-pac middl east africa also emphas broadli
foreign exchang risk roughli net sale gener
oper outsid unit state expos exchang rate fluctuat
includ british pound canadian dollar euro indian rupe chines renminbi
importantli fluctuat fx rate could advers affect net sale profit cash
flow believ could experi million million net sale
adjust ebitda impact respect /- chang eur/usd rate
ipo price per share may ev/ebitda lower
end revis rang base million common share note previous
intend offer million share rang first day
trade avtr share price increas mere close day
sinc stock price increas vs per share
impli market cap billion vs thermo fisher billion
avtr share current trade price-to-earnings ev/ebitda multipl
respect discount competitor thermo fisher ev/ebitda
basi discount broader peer group believ valuat fulli
reflect tangibl growth driver synergi opportun target price base
ebitda still discount broader peer group life scienc compani
better reflect build exposur faster-grow higher margin product
line end market well line sight near-term vwr synergi
blue sky scenario predic better-than-expect synergi captur
relat acquisit continu improv effort driven
vs averagehistor averag announc acquisit vwr may charl martineau pm univers toronto
avantor busi system acceler penetr growth emerg market
well sustain strength biopharma end-market
grey sky scenario base lower-than-expect synergi captur
relat acquisit integration-rel miscu slow
 spend across broader biopharma end-market heighten competit
note cover matt miksic
perspect life scienc valuat alreadi notabl elev reflect healthi
fast-grow underli fundament life scienc experienc increas
invest focu critic tool develop new therapeut
associ product life scienc compani histor trade premium
broader pursuant life scienc see figur
cspriceupsid dailyrevenu cy average cy average p/sale cy price-to-earnings cy ev/ebitda cy tickerratingtargetdownsidepricecap volume scienc fisher corp charl martineau pm univers toronto figur price-to-earnings life scienc vs
discount cash flow model predic avtr profit margin expand
bp averag annual next year project capit expenditur
million million expenditur grow thereon support
valuat stock wacc use reflect billion outstand
debt balanc equiti risk premium target price also support
dcf-deriv valuat shown figur better-than-expect profit margin growth
greater synergi captur continu improv busi
price-to-earnings price-to-earnings average lst index average spxhistor averag histor averag averag charl martineau pm univers toronto figur discount analysi million except per share amount
figur return invest capit analysi
base holt analysi rel strong document correl
valuat coverag univers includ pharmaceut suppli
chain servic anim health dental contract research organ life
scienc tool diagnost compani suggest investor focus true
econom return appli regress market valuat vs cfroi use
estim compani indic variat valuat determin
consequ holt cfroi correl indic market will
futur growthchg work fix assets- increment invest cash flowpv pv residu debt prefer per charl martineau pm univers toronto
pay compani gener higher return invest capit simpli
stronger ep growth believ recent merger synergi
thereon increment opportun continu oper effici effort set
stage improv holt regress indic trade
line best fit suggest upsid support outperform view
figur holt analysi support outperform thesi
manag team compris veteran relev life scienc biotechnolog
chemic industri industri importantli sever key execut
extens experi legaci fundament recent
acquisit subsequ integr effort relat board
director includ one member avtr manag ceo chairman
board rajiv gupta senior advisor new mountain capit llc privat equiti
invest firm base new york note new mountain capit current three
design board member affili goldman sach current two prior
consumm offer robert fine serv board director design
psp current three independ director includ jonathan peacock
rakesh sachdev christi shaw
nameposit agebiographymiachel stubblefielddirector presid chief execut becom presid ceo mr stubblefield senior expert chemic practic mckinsey compani held varieti role corpor szlosekevp chief join decemb mr szlosek serv svp chief offic april august serv varieti role honeywel increas respons sinc bramwellevp strateg current role serv svp strateg partner global export vwr posit held march novemb june march seve vwr svp strateg partner presid southwest mexico ger brophyevp biopharma brophi join spent year varieti senior level posit recent head cell therapi life scienc januari chief technolog offic life scienc april vice-president new product develop medic diagnost juli couturierevp servic strategi busi transform join mr couturi serv chief execut offic salicornia llc septemb april chief offic ovasci septemb juli prior ovasci spent year millipor sigma held varieti posit includ servic merger integr gener manag financ consult bjorn hofmanevp chief oper assum current role evp research develop novemb previous serv chief oper offic evp busi oper gener manag europ kulkarnievp chief technolog kulkarni join chief technolog offic prior join serv chief technolog innov offic corpor vice-president research develop advanc engin materi emuls busi unit eric mcallisterevp chief join march mr mcallist serv svp westinghous electr compani feburari also previous serv global vice-president danah chief offic omnitur senior director justin millerevp gener counsel join decemb mr miller serv counsel ballard spahr llp decemb decemb prior ballard spahr mr miller spent year dupont number role includ associ gener counsel chief litig counsel assist chief intellectu properti counsel devashish ohrievp ohri serv posit sinc prior join act manag director south asia freder vanderhaegenevp join mr vanderhaegen serv vice-president gener manag emea ortho clinic diagnost june octob vice-president sale beckman coulter octob june corey walkerevp america biomateri advanc walker serv evp biomateri advanc technolog sinc june given addit respons lead america region prior join mr walker act global vice-president sperri drill servic multichem global busi group halliburton energi servic miachel wondraschevp chief inform join mr wondrasch serv global chief technolog offic januari april prior mr wondrasch svp chief technolog offic pepsico juli decemb serv varieti leadership posit april juli charl martineau pm univers toronto
figur quarterli ep million except per share amount
histor gener expens incom incom avail loss attribut non-controlling incom common basic share dilut share gener gener charl martineau pm univers toronto
figur quarterli revenu million
figur annual ep million except per share amount
histor gener expens incom incom avail loss attribut non-controlling incom common basic share dilut share analysistot gener incom avail incom common analysistot gener incom common charl martineau pm univers toronto
figur annual revenu million
figur balanc sheet million
asset receiv net current relationship net accumul finite-liv intang asset net accumul amort indefinite-l liabil current portion payabl current debt debt net current incom tax prefer -- -- -- -- -- -- -- -- junior convert prefer stock includ paid comprehens stockhold interest -- -- -- -- -- -- -- -- -- -- -- total liabil stockhold charl martineau pm univers toronto
figur histor project flow million
activitiesnet loss non-controlling interest discontinu oper -- -- -- -- -- -- -- -- -- -- -- adjust reconcil net incom share-bas compens defer incom tax benefit -- -- -- -- -- -- -- -- -- loss extinguish debt -- -- -- -- -- -- -- -- -- -- -- transit tax liabil -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- chang oper asset liabil exclud effect acquisit account account asset -- -- -- -- -- -- net provid oper activitiescapit paid acquisit net cash acquir -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- net use invest activitiesissu seri prefer stock warrant net fee -- -- -- -- -- -- -- issuanc junior convert prefer stock net fee -- -- -- -- -- -- debt -- -- -- -- -- -- -- -- -- debt cpec -- -- -- -- -- -- -- paid debt financ cost -- -- -- -- -- -- -- -- -- -- -- distribut -- -- -- payment conting -- -- -- -- -- -- -- -- -- -- net provid use financ rate effect -- -- -- -- -- -- increas cash equival begin equival end charl martineau pm univers toronto
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
compani mention price
labcorp america lh
